Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SNCE Science 37 (SNCE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Science 37 Stock (NASDAQ:SNCE) 30 days 90 days 365 days Advanced Chart Get Science 37 alerts:Sign Up Key Stats Today's Range$5.75▼$5.7550-Day Range$5.68▼$5.7552-Week Range$3.73▼$12.96VolumeN/AAverage Volume43,227 shsMarket Capitalization$34.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewScience 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.Read More… Receive SNCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter. Email Address SNCE Stock News HeadlinesClinical researcher, cabinet maker cancel North Carolina jobs grants citing financial challenges, acquisitionsJanuary 14, 2025 | msn.comScience 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access InnovationJanuary 14, 2025 | tmcnet.comWall St turns to THIS catalyst after Trump’s inaugurationWall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger than his inauguration. As soon as January 29th…January 20, 2025 | Timothy Sykes (Ad)Science 37 nearly doubles U.S. enrollment for GSK Phase 3 rare disease trialNovember 21, 2024 | markets.businessinsider.comTest scores in Kentucky show mixed results, including low performance in scienceOctober 3, 2024 | msn.comScience 37 Unveils New Corporate Headquarters in Research Triangle Park, NCAugust 6, 2024 | globenewswire.comHow ‘Evo Moment #37’ Became the Greatest Viral Clip in Esports HistoryJuly 20, 2024 | msn.comScience 37 Enrolls 42% of Trial Cohort in 8 WeeksJuly 19, 2024 | tmcnet.comSee More Headlines SNCE Stock Analysis - Frequently Asked Questions When did Science 37's stock split? Shares of Science 37 reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Science 37 own? Based on aggregate information from My MarketBeat watchlists, some other companies that Science 37 investors own include Meta Platforms (META), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Broadcom (AVGO), Builders FirstSource (BLDR), Adobe (ADBE) and Advanced Micro Devices (AMD). Company Calendar Today1/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolNASDAQ:SNCE CUSIPN/A CIK1819113 Webwww.lifesciacquisition.com Phone984-377-3737FaxN/AEmployees460Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($21.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,990,000.00 Net Margins-206.86% Pretax Margin-207.00% Return on Equity-83.09% Return on Assets-61.58% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio4.17 Sales & Book Value Annual Sales$60.26 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value$16.70 per share Price / Book0.34Miscellaneous Outstanding Shares5,970,000Free Float5,564,000Market Cap$34.33 million OptionableNot Optionable Beta0.55 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:SNCE) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Science 37 Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Science 37 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.